抗辐射性
癌症研究
DNA修复
雷达51
脱甲基酶
染色质
组蛋白
生物
表观遗传学
DNA损伤
同源重组
染色质重塑
DNA甲基化
范卡
DNA错配修复
重编程
细胞生物学
小RNA
组蛋白H2A
PEDF公司
基因组不稳定性
癌变
化学
癌症表观遗传学
核苷酸切除修复
Ku70型
癌症
放化疗
合成致死
表观遗传学
医学
EZH2型
作者
Baoqing Tian,Hua Zhang,Jiao Ren,Jupeng Yuan,Songyue Guo,Yue Shen,Xinyi Huang,Zengfu Zhang,Xianrui Shan,Yongchun Xie,Fei Wang,Ying Xu,Jiayi Liu,Meng Wu,Jinming Yu,Dawei Chen
标识
DOI:10.1038/s41418-026-01814-6
摘要
Radioresistance remains a major barrier in esophageal squamous cell carcinoma (ESCC). This study demonstrates small nucleolar RNA SNORA23 as a pathogenic epigenetic driver of intrinsic radioresistance, with its overexpression tightly correlating with advanced T-stage, lymph node metastasis, and adverse clinical outcomes in a chemoradiotherapy cohort. Mechanistically, SNORA23 directly binds the ARID domain of histone demethylase KDM5C via a structurally defined G11-Ser169 interface-obstructing KDM5C chromatin binding to derepress DNA repair scaffolding gene SFPQ. This chromatin reprogramming enables SFPQ-facilitated recruitment of RAD51 and Ku80 to DNA double-strand breaks, accelerating homologous recombination (HR) and non-homologous end joining (NHEJ). SFPQ high expression recapitulates SNORA23-mediated repair enhancement and reduced radiosensitivity. Therapeutically, SNORA23-targeting antisense oligonucleotides (ASOs) disrupt this axis, impair DNA repair, and synergize with radiotherapy to suppress tumor growth and prolong survival in vivo without evident systemic toxicity These findings define a snoRNA-chromatin-repair axis driving therapeutic resistance and support SNORA23 inhibition as a promising strategy to overcome radioresistance in ESCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI